论文部分内容阅读
从1958年Arnold等人合成环磷酰胺(CTX)以来,作为一种抗癌药物已在临床上广泛应用。随后,人们发现CTX 对机体的免疫功能具有抑制作用。近年来,人们对CTX 选择性灭活抑制性T 细胞(Ts)的作用做了不少的研究,发现在一定条件下,低剂量CTX 对动物和人的免疫功能具有放大作用,并可增强载瘤宿主的排斥反应。CTX 对迟发超敏反应的放大作用自从Maguire 等人1967年首先在豚鼠上发现CTX 对二硝基氯苯(DNCB)所致迟发性超敏反应(DTH)具有加强作用以来,不少学者对此做了进一步研究。Askenase等研究了CTX 对绵羊红细胞在不同种系的小鼠所致的DTH 影响及抗体生成的作用。先用CTX 给小鼠注射,二天后静脉给予不同剂量
Since Arnold et al. synthesized cyclophosphamide (CTX) in 1958, it has been widely used clinically as an anticancer drug. Subsequently, it was found that CTX has an inhibitory effect on the body’s immune function. In recent years, people have done a lot of research on the role of CTX selective inactivation of suppressor T cells (Ts) and found that under certain conditions, low dose CTX has an amplification effect on the immune function of animals and humans, and can enhance the Tumor host rejection. Amplification of Latex Hypersensitivity by CTX Since Maguire et al. first discovered that CTX has a potentiating effect on delayed hypersensitivity (DTH) induced by dinitrochlorobenzene (DNCB) in guinea pigs in 1967, many scholars have This has been further studied. Askenase et al. studied the effect of CTX on the DTH and antibody production of sheep red blood cells in different germline mice. The mice were injected with CTX first, and two doses were given intravenously two days later.